Background

Treatment for malignant melanoma has significantly improved survival rates since the introduction of immune checkpoint inhibitors (ICI). Antibody therapies targeting Programmed Cell Death Protein 1 (PD-1) or Cytotoxic T-Lymphocyte Associated Antigen 4 (CTLA-4) have provided long-term survival for some patients. Conversely, many patients experience disease progression due to a lack of response to initial treatment or the development of resistance during administration.

To target this refractory patient group, autologous tumor-infiltrating lymphocyte (TIL) cell therapy—which involves collecting lymphocytes from a patient's own tumor tissue, expanding them ex vivo, and re-infusing them—has emerged as an alternative. The principle involves injecting a large number of antigen-recognizing T cells adapted to the tumor microenvironment to directly attack solid tumors.

First-generation TIL therapy required the administration of high-dose interleukin-2 (IL-2) to support the survival and proliferation of the injected cells. High-dose IL-2 frequently causes capillary leak syndrome, hypotension, nephrotoxicity, and cardiovascular side effects. The systemic toxicity imposed on patients was so severe that intensive care unit (ICU) monitoring was essential, making it difficult to apply to elderly patients or those with underlying conditions. This background has driven a continuous demand for technical alternatives in the solid tumor-targeted cell therapy field to reduce or eliminate dependence on IL-2 adjuvant therapy.

Key Findings

Early clinical results for the next-generation autologous TIL therapy candidate amsokigene autoleucel were presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, according to an analysis reported in Nature Medicine.

Amsokigene autoleucel is an autologous cell therapy genetically engineered to allow T cells to survive and proliferate in vivo without the need for external IL-2 administration. Researchers reviewed data obtained through a non-prespecified pooled analysis of two ongoing clinical trials. The analysis targeted a cohort of refractory advanced melanoma patients who had failed previous ICI treatment or experienced disease progression.

The results showed that despite the complex genetic engineering process, amsokigene autoleucel demonstrated a stable manufacturing success rate sufficient for administration to all target patients. This indicates that T cell activity and phenotype were fully maintained during the ex vivo manipulation process.

Patient tolerability after administration was also favorable. By omitting the concomitant administration of exogenous high-dose IL-2, the incidence of severe systemic capillary leak syndrome and fatal hemodynamic instability, which are frequently reported in traditional TIL therapies, was significantly reduced. Clinical indicators have been observed that could substantially reduce the burden of ICU admission associated with high-dose cytokine infusion.

Furthermore, preliminary efficacy signals indicating tumor shrinkage were observed in a cohort of patients with advanced melanoma who had ceased responding to ICI treatment. This supports the finding that genetically engineered TILs successfully engrafted and exerted their anti-tumor activity within the tumor microenvironment of patients facing resistance barriers.

Implications and Outlook

This achievement presents a turning point for expanding the therapeutic window of TIL therapy, which was previously constrained by high-dose cytokine toxicity. It demonstrates that a cell therapy designed to maintain its own survival signals without IL-2 administration can function in actual cancer patients. This opens the possibility of expanding the accessibility of cell therapy—which was previously limited to large specialized cancer hospitals equipped with special isolation wards due to severe systemic side effects—to the level of general clinical institutions.

The subsequent challenges are also clear. It should be noted that the reported results are based on a post hoc pooled analysis of two clinical trials, rather than a single pre-planned randomized controlled trial. It is difficult to exclude heterogeneity between cohorts, and the patient population size is still limited. To confirm meaningful improvements in overall survival and objective response rates, large-scale prospective confirmatory trials must follow.

The addition of the genetic engineering process may increase manufacturing time and cost, and whether unknown immune adverse reactions occur due to long-term in vivo persistence remains an issue to be elucidated through long-term follow-up.